Cerivastatin

CHEMBL1477 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
459.5 g/mol
LogP
3.6
Phase
4

A synthetic HMG-CoA reductase inhibitor (statin) used to lower LDL cholesterol and reduce cardiovascular risk. It was voluntarily withdrawn from the worldwide market in 2001 due to an unacceptably high incidence of potentially fatal rhabdomyolysis, particularly when combined with gemfibrozil. It represents an important pharmacovigilance case study in post-marketing drug safety.

น้ำหนักโมเลกุล

459.5000 g/mol

LogP

3.60

TPSA

99.90 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1

InChI

InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1

Molecular Formula

C26H34FNO5

HBD / HBA

3 / 7

พันธะที่หมุนได้

11

อะตอมหนัก

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A synthetic HMG-CoA reductase inhibitor (statin) used to lower LDL cholesterol and reduce cardiovascular risk. It was voluntarily withdrawn from the worldwide market in 2001 due to an unacceptably high incidence of potentially fatal rhabdomyolysis, particularly when combined with gemfibrozil. It represents an important pharmacovigilance case study in post-marketing drug safety.

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Yes, Cerivastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1477. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 446156. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.